Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.

IF 5.2 Q1 DERMATOLOGY

Psoriasis (Auckland, N.Z.) Pub Date : 2018-03-23 eCollection Date: 2017-01-01 DOI:10.2147/PTT.S161437

Florian Anzengruber, Adhideb Ghosh, Julia-Tatjana Maul, Mathias Drach, Alexander A Navarini

{"title":"Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.","authors":"Florian Anzengruber, Adhideb Ghosh, Julia-Tatjana Maul, Mathias Drach, Alexander A Navarini","doi":"10.2147/PTT.S161437","DOIUrl":null,"url":null,"abstract":"Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions.Patients and methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study.Results: There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index.Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6- patients.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2018-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S161437","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psoriasis (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PTT.S161437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 10

Abstract

Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions.

Patients and methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study.

Results: There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index.

Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6- patients.

Abstract Image

查看原文本刊更多论文

HLA-Cw6基因分型在ustekinumab治疗下银屑病患者预后预测中的有限临床应用:一项单中心回顾性分析

目的:几项研究表明，HLA-Cw6+等位基因可以预测银屑病患者治疗结果的改善。该研究的目的是评估已发表的HLA-Cw6等位基因携带者与ustekinumab应答之间的关联是否有可能影响治疗决策。患者和方法:银屑病活动性和严重程度指数50、75、90的差异指甲银屑病严重程度指数;在HLA-Cw6等位基因携带者与非携带者之间评估16周时的皮肤病学生活质量指数。我们的研究纳入了30例接受ustekinumab治疗的中重度牛皮癣患者。结果:两组在银屑病活动度和严重程度指数50、75、90、指甲银屑病严重程度指数和皮肤科生活质量指数变化方面无差异。结论:在我们回顾性分析的队列中，我们没有发现先前报道的HLA-Cw6+与HLA-Cw6-患者的更好反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psoriasis (Auckland, N.Z.)

自引率

0.00%

发文量

审稿时长

16 weeks